Based on our evidence that Anxa2 was differentially regulated in Col2.3+ cells in AML versus CML (Supplementary Fig. 1A, B)4, we showed that Anxa2 expression was higher in Sca1+ CD73+ mesenchymal stromal cells (MSC) from an AML versus a CML BMM (Supplementary Fig. 1C, D, Tables 1, 2). The gene discussed is ANXA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.